You are here

  • Home
  • Archive
  • Volume 20, Issue 7
  • A Phase 2 Evaluation of Irofulven as Second-line Treatment of Recurrent or Persistent Intermediately Platinum-Sensitive Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Trial

Article metrics

Article menu
Download PDFPDF
Ovarian Cancer
A Phase 2 Evaluation of Irofulven as Second-line Treatment of Recurrent or Persistent Intermediately Platinum-Sensitive Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Trial

 

Online download statistics by month:

Online download statistics by month: January 2019 to October 2024

AbstractFullPdf
Jan 2019400
Feb 20191200
Mar 20192301
Apr 2019700
May 20191200
Jun 20191000
Jul 20191200
Aug 2019600
Sep 2019400
Oct 2019600
Nov 20191302
Dec 20191600
Jan 20201601
Feb 2020400
Mar 20202602
Apr 2020400
May 20201800
Jun 20201000
Jul 20201700
Aug 20203000
Sep 20203003
Oct 2020600
Nov 2020800
Dec 20202000
Jan 20212301
Feb 20211800
Mar 2021400
Apr 20211200
May 2021700
Jun 2021100
Aug 2021001
Oct 20212000
Nov 20211200
Dec 20211200
Jan 20222600
Feb 20222000
Mar 20223300
Apr 20221401
May 20223800
Jun 20223401
Jul 20223600
Aug 20225600
Sep 20224201
Oct 20224600
Nov 20225002
Dec 20222000
Jan 20231800
Feb 20238000
Mar 20232400
Apr 2023600
May 2023200
Jun 20232702
Jul 20232500
Aug 20231000
Sep 2023500
Oct 2023600
Nov 20231601
Dec 20233200
Jan 20241400
Feb 2024200
Mar 20242800
Apr 20243300
May 20243600
Jun 20241900
Jul 20243800
Aug 20243600
Sep 20242400
Oct 2024200
Total1321019